Mycophenylate mofetil: what role in the treatment of lupus?

Abstract

Improved patient survival following lupus nephritis with the institution of corticosteroids, immunosuppressants and renal replacement therapy allows greater emphasis on long-term management issues. In particular, the recent focus has been on therapies to treat nephritis with fewer adverse effects of cyclophosphamide-including immunosuppressive regimens. Mycophenolate mofetil (MMF) has been used in the field of transplantation for more than 10 years. Following initial anecdotal reports describing benefits of MMF in the treatment of lupus nephritis, randomized, controlled trials have established a role for MMF in the treatment of lupus nephritis. MMF use to treat other lupus manifestations has been evaluated only in anecdotal case reports or series with few well-designed trials. Issues complicating clinical trial design in lupus including appropriate use and interpretation of activity and damage indices, comparable remission and response criteria and stratification of high risk populations have been the subject of much discussion and emerging consensus. As long-term outcomes in lupus improve, the toxicity of therapy and risk of relapse become increasingly important determinants of choice of therapeutic agents.

Keywords

autoimmunity glomerulonephritis immunosuppressive therapy lupus nephritis mycophenylate mofetil

Get full access to this article

View all access options for this article.

References

Allison AC. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenylate mofetil in transplantation . Transplant Proc 1994; 26: 3205-3210 .

The Tricontinental Mycophenolate Mofetil Study Group . A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation . Transplantation 1996; 61: 1029-1029 .

Dooley MA , Cosio FG , Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations . J Am Soc Nephrol 1999; 10: 833-839 .

Kapitsinou PP , Boletis JN , Skopouli FN , Boki KA , Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate mofetil . Rheumatology 2004; 43: 377-380 .

Kingdon EJ , McLean AG , Psimenous E et al. The safety and efficacy of MMF in lupus nephritis: a pilot study . Lupus 2001; 10: 606-611 .

Chan TM , Li FK , Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group . N Engl J Med 2000; 343: 1156-1162 .

Hu W , Liu Z , Chen H et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis . Chin Med J 2002; 115: 705-709 .

Ong LM , Hooi LS , Lim To et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycopeholate mofetil in the induction therapy of proliferative lupus nephritis . Nephrology 2005; 10: 504-510 .

Ginzler EM , Dooley MA , Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide induction therapy in lupus nephritis . N Engl J Med 2005; 353: 2219-2228 .

10.

Contreras G , Pardo C , Leclercq B et al. Sequential therapies for proliferative lupus nephritis . New Engl J Med 2004; 350: 971-980 .

11.

Austin HA III , Klippel JH , Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs . N Engl J Med 1986; 314: 614-619 .

12.

Boumpas DT , Austin HA III , Vaughan EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet 1992; 34: 741-745 .

13.

Gourley MF , Austin HA III , Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Annals Intern Med 1996; 125: 549-557 .

14.

Alarcon GS , Friedman AW , Straaton KV et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture . Lupus 1999; 8: 197-209 .

15.

Cooper GS , Parks CG , Treadwell EL et al. Differences by race, sex, and age in the clinical and immunologic features of recently-diagnosed systemic lupus erythematosus patients in the southeastern United States . Lupus 2002; 11: 161-167 .

16.

Dooley MA , Hogan S , Jennette C , Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans . Kidney Int 1997; 51: 1188-1195 .

17.

Austin HA III , Boumpsas DT , Vaughan EM et al. High-risk features of lupus nephritis: importance of race and clinical histological factors in 166 patients . Nephrol Dial Transplant 1995; 10: 1620-1628 .

18.

Velasquez X , Verdejo U , Massardo L et al. Outcome of Chilean patients with lupus nephritis and response to intravenous cyclophosphamide . J Clin Rheumatol 2003; 9: 7-14 .

19.

Ioannidis JPA , Boki KA , Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide . Kidney Int 2000; 57: 258-264 .

20.

Illei GG , Takada K , Parkin D. Renal flares are common in patients with severe proliferative lupus nephritis treated with immunosuppressive therapy: longterm followup of a cohort of 145 patients participating in randomized controlled studies . Arthritis Rheum 2002; 46: 995-1002 .

21.

Mok CC , Ying KY , Tang S et al. Predictors and outcomes of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis . Arthritis Rheum 2004; 50: 2559-2568 .

22.

Moroni G , Quaglini S , Maccario M , Banfi G , Ponticelli C. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis . Kidney Int 1996; 50: 2047-2053 .

23.

Houssiau FA , Vasconcelos C , D’Cruz D. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide . Arthritis Rheum 2002; 46: 2121-2131 .

24.

Houssiau FA , Vasconcelos C , D’Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from the long-term follow-up of the Euro-Lupus Nephritis Trial . Arthritis Rheum 2004; 50: 3934-3940 .

25.

Chan TM , Tse KC , Tang CS , Lai KN , Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine . Lupus 2005; 14: 263-264 .

26.

Chan TM , Tse KC , Tang CSO , Mok MY , Li FK , for the Hong Kong Nephrology Study Group . Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis . J Am Soc Nephrol 2005; 16: 1076-1084 .

27.

Gaubitz M , Schorat A , Schotte H , Kern P , Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial . Lupus 1999; 8: 731-736 .

28.

Karim MY , Pisoni CN , Ferro L et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy . Rheumatology 2005; 44: 1317-1321 .

29.

Alba P , Karim MY , Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune hemolytic anemia in patients with systemic lupus erythematosus and antiphospholipid syndrome . Lupus 2003; 12: 633-635 .

30.

Jose J , Paulose BK , Vasuki Z , Danda D. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil . Lupus 2003; 12: 630-632 .

31.

Samad AS , Lindsley CB. Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil . Southern Med J 2003; 96: 705-707 .

32.

Schanz S , Ulmer A , Rassner G , Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil . British Journal of Dermatology 2002; 147: 174-179 .

33.

Goyal S , Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil . J Am Acad Dermatol 2001; 45: 142-144 .

34.

Pisoni CN , Obermoser G , Cuadrado MJ et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil . Clin Exp Rheumatol 2005; 23: 393-396 .

35.

Bijl M , Horst G , Bootsma H , Limburg PC , Kallenberg CG. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk . Ann Rheum Dis 2003; 62: 534-539 .

36.

Ahmadi-Simab K , Lamprecht P , Gross WL. Progression of lupus nephritis during treatment with mycophenolate mofetil . Annals of the Rheumatic Diseases 2004; 63: 1179-1180 .

37.

Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE . Arthritis Rheum 1992; 35: 630-640 .

38.

Hay EM , Bacon PA , Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus . Q J Med 1993; 86: 447-458 .

39.

Gladman DD , Goldsmith CH , Urowitz MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison . J Rheumatol 2000; 27: 373-376 .

40.

US Department of Health and Human Services FDA Center for Drug Evaluation and Research . Guidance for industry systemic lupus erythematosus - developing drugs for treatment. Retrieved 17 February 2006 from http://www.fda.gov/cder/guidance/6496dft.htm